Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 28, 2017
Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor SizesStig Palm, Tom Bäck, Sture Lindegren, et al.
Scientific Reports|July 15, 2015
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trialsEmma Aneheim, Per Albertsson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with <sup>211</sup>At-MX35-F(ab')<sub>2</sub>: Influence of Absorbed Tumor Dose and Effect on Long-Term SurvivalTom Bäck, Nicolas Chouin, Sture Lindegren, et al.
EJNMMI Radiopharmacy and Chemistry|November 13, 2024
Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapyChiara Timperanza, Anna Gustafsson-Lutz, Tom Bäck, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 24, 2024
A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells <i>In Vitro</i>Tom Bäck, Per Albertsson, Emma Aneheim, et al.
EJNMMI Research|April 6, 2013
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAbSophie E Eriksson, Tom Bäck, Erika Elgström, et al.
Cancer Biotherapy & Radiopharmaceuticals|December 23, 2009
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude miceTom Bäck, Börje Haraldsson, Ragnar Hultborn, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.
Bioconjugate Chemistry|January 22, 2016
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide ImmunoconjugatesEmma Aneheim, Anna Gustafsson, Per Albertsson, et al.
Pageof 5